X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA DIVIS LABORATORIES ELDER PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x -0.2 38.4 - View Chart
P/BV x 0.1 6.2 1.6% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ELDER PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
DIVIS LABORATORIES
Mar-18
ELDER PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3801,142 33.3%   
Low Rs188533 35.3%   
Sales per share (Unadj.) Rs491.2146.6 335.1%  
Earnings per share (Unadj.) Rs-3.233.0 -9.6%  
Cash flow per share (Unadj.) Rs14.438.4 37.5%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.2 0.0%  
Book value per share (Unadj.) Rs376.5222.8 169.0%  
Shares outstanding (eoy) m20.54265.47 7.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.65.7 10.1%   
Avg P/E ratio x-89.325.3 -352.1%  
P/CF ratio (eoy) x19.721.8 90.4%  
Price / Book Value ratio x0.83.8 20.1%  
Dividend payout %030.3 0.0%   
Avg Mkt Cap Rs m5,833222,318 2.6%   
No. of employees `000NA10.8 0.0%   
Total wages/salary Rs m2,1794,561 47.8%   
Avg. sales/employee Rs ThNM3,616.0-  
Avg. wages/employee Rs ThNM423.8-  
Avg. net profit/employee Rs ThNM814.9-  
INCOME DATA
Net Sales Rs m10,08938,915 25.9%  
Other income Rs m2571,134 22.6%   
Total revenues Rs m10,34640,049 25.8%   
Gross profit Rs m-79212,617 -6.3%  
Depreciation Rs m3611,425 25.4%   
Interest Rs m2,75613 20,724.1%   
Profit before tax Rs m-3,65312,313 -29.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m1253,543 3.5%   
Profit after tax Rs m-658,770 -0.7%  
Gross profit margin %-7.832.4 -24.2%  
Effective tax rate %-3.428.8 -11.9%   
Net profit margin %-0.622.5 -2.9%  
BALANCE SHEET DATA
Current assets Rs m9,24045,351 20.4%   
Current liabilities Rs m9,9986,507 153.6%   
Net working cap to sales %-7.599.8 -7.5%  
Current ratio x0.97.0 13.3%  
Inventory Days Days46127 36.6%  
Debtors Days Days6095 63.0%  
Net fixed assets Rs m10,12421,160 47.8%   
Share capital Rs m206531 38.7%   
"Free" reserves Rs m5,58258,625 9.5%   
Net worth Rs m7,73459,156 13.1%   
Long term debt Rs m4,8890-   
Total assets Rs m22,88267,832 33.7%  
Interest coverage x-0.3926.8 -0.0%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.6 76.9%   
Return on assets %11.812.9 90.8%  
Return on equity %-0.814.8 -5.7%  
Return on capital %22.320.8 107.1%  
Exports to sales %3.00-   
Imports to sales %0.421.8 2.0%   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m438,485 0.5%   
Fx inflow Rs m30732,359 0.9%   
Fx outflow Rs m1259,042 1.4%   
Net fx Rs m18123,317 0.8%   
CASH FLOW
From Operations Rs m11,7547,759 151.5%  
From Investments Rs m-561-4,783 11.7%  
From Financial Activity Rs m-6,762-3,142 215.2%  
Net Cashflow Rs m4,432-166 -2,669.7%  

Share Holding

Indian Promoters % 39.6 52.0 76.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 11.8 63.6%  
FIIs % 16.8 19.0 88.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 17.2 209.9%  
Shareholders   16,479 31,796 51.8%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  BIOCON LTD  PFIZER  ALKEM LABORATORIES  

Compare ELDER PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

BIOCON LTD at All Time High; BSE HEALTHCARE Index Up 0.7% (Market Updates)

Sep 19, 2018 | Updated on Sep 19, 2018

BIOCON LTD share price has hit an all time high at Rs 695 (up 1.6%). The BSE HEALTHCARE Index is up by 0.7%. Among the top gainers in the BSE HEALTHCARE Index today are BIOCON LTD (up 1.6%) and SANOFI INDIA (up 0.4%). The top losers include PIRAMAL ENTERPRISES and LUPIN LTD (down 0.1%).

DIVIS LABORATORIES at All Time High; BSE HEALTHCARE Index Up 1.2% (Market Updates)

Sep 19, 2018 | Updated on Sep 19, 2018

DIVIS LABORATORIES share price has hit an all time high at Rs 1,406 (up 1.8%). The BSE HEALTHCARE Index is up by 1.2%. Among the top gainers in the BSE HEALTHCARE Index today are DIVIS LABORATORIES (up 1.8%) and SANOFI INDIA (up 0.4%). The top losers include ABBOTT INDIA (down 0.1%) and ALEMBIC PHARMA (down 0.2%).

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS